Medical device major Boston Scientific Corporation BSX recently announced the receipt of the European CE mark for its LOTUS Edge Valve System. This device is the latest of the company’s next generation transcatheter valve implantation (TAVI) technology. Following the approval, the LOTUS Edge device will be available in selected centers in Europe.
The LOTUS Edge valve system is used for aortic valve replacement in patients suffering from severe aortic stenosis and in need of surgical valve replacement. Unlike the traditional systems, which require open heart surgery, under this latest system, the replacement valve is delivered via transcatheter percutaneous delivery, a minimally invasive procedure involving a small incision to gain access to a blood vessel.
Like the earlier Lotus Valve system, this edge valve system accurately relocates the device and prevents paravalvular leak. However the new system carries a more flexible and lower profile catheter for easy use. It also includes Depth Guard technology, which reduces the use of permanent pacemakers (PPM).
According to Monash Medical Centre in Melbourne, Australia, Boston Scientific’s LOTUS Edge device is a better version of its predecessor. Recent studies have shown that the new one incorporates the Adaptive Seal technology, which minimizes paravalvular regurgitation (leaking) in most of the patients. LOTUS Edge continues to be the sole TAVI device, which allows physicians to perform valve replacement in an easier and convenient procedure for best results.
As per Research and Markets report, the global heart valves market is estimated to grow at a CAGR of 14.28% during 2016-2020. This growing trend is primarily based on the increasing awareness about modern valve technology in treating heart diseases by physicians. This trend reveals huge opportunity for the interventional cardiology business of Boston Scientific, helping the company in capturing the untapped potential of the heart valves market.
Further, Boston Scientific has recently recorded a significant 12% revenue growth in its interventional cardiology segment. The approval will encourage Boston Scientific to continuously develop technology for clinicians to effectively treat patients with severe aortic stenosis.
Zacks Rank & Key Picks
Boston Scientific currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical product sector are GW Pharmaceuticals plc GWPH, NuVasive, Inc. NUVA and Quidel Corp. QDEL. All these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research